Ask Lazlo

life sciences… only

Not another PML case…

Biogen Idec announced on Wednesday (Oct. 29, 2008) that another case of┬áprogressive multifocal leukoencephalopathy (PML) has been reported in a patient receiving the company’s multiple sclerosis (MS) drug, Tysabri. ┬áThis is the sixth overall case of PML reported in patients taking Tysabri and the third since the drug was reintroduced on the market in June 2006.

The news has again affected the commercial outlook of Biogen Idec Continue reading


October 31, 2008 Posted by | Biotech | , , , | Leave a comment